Enables more frequent FDA engagement, rolling Biologic License Application review, and the potential for Accelerated Approval and Priority Review upon successful clinical development Advances AP-SA02 ...
LOS ANGELES, April 27, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of ...
Hosted on MSN
The T-14 Armata’s hidden flaws exposed
It's called the world's most advanced tank, but its problems run deep. Uncover the technical and logistical failures that cast serious doubt on the Russian Armata's real combat power. US attacks ...
Armata Pharmaceuticals’ investigational phage therapy, AP-SA02, demonstrated earlier resolution in patients with Staphylococcus aureus bacteremia (SAB) in a Phase IIa trial, reinforcing the growing ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
- GAAP revenue was $2.2 million, outpacing the $1.38 million GAAP consensus estimate due to strong grant and award funding. - Net loss widened significantly to $0.45 per share (GAAP). - Armata ...
New Delhi: US President Donald Trump is not happy with India and Russia’s friendship and is threatening both countries with tariffs. Amidst this, the two countries are discussing a crucial defence ...
Pax Armata in Battlefield 6 is the fictional world's leading private military company. It is also the game's main antagonist. However, there may be more than just that. It may be supported by a ...
Jake is a writer from the United Kingdom. With a focus on first-person shooters, RPGs, and achievement hunting, writing about the gaming industry comes naturally and is a real point of pride. Outside ...
Armata Pharmaceuticals has posted early validation of its phage platform. The phase 1b/2a trial linked a bacteriophage cocktail to improved outcomes in patients with bacteria in their blood, opening ...
LOS ANGELES - Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a biotechnology company specializing in bacteriophage therapeutics, has received an additional $4.65 million from the U.S. Department ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results